Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Over the last 12 months, insiders at Bicycle Therapeutics plc have bought $0 and sold $663,411 worth of Bicycle Therapeutics plc stock.
On average, over the past 5 years, insiders at Bicycle Therapeutics plc have bought $0 and sold $8.02M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 628,572 shares for transaction amount of $8.8M was made by Cambridge Innovation Capital (Jersey) Ltd (10 percent owner) on 2019‑05‑29.
2024-04-11 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 257 0.0006% | $22.49 | $5,780 | +1.02% | |
2024-04-03 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 3,158 0.0076% | $23.81 | $75,192 | -2.53% | |
2024-04-03 | Sale | Skynner Michael | CHIEF TECHNOLOGY OFFICER | 955 0.0023% | $23.81 | $22,739 | -2.53% | |
2024-04-03 | Sale | Milnes Alistair | CHIEF OPERATING OFFICER | 955 0.0023% | $23.81 | $22,739 | -2.53% | |
2024-04-03 | Sale | Keen Nicholas | CHIEF SCIENTIFIC OFFICER | 790 0.0019% | $23.81 | $18,810 | -2.53% | |
2024-04-03 | Sale | Crockett Nigel | CHIEF BUSINESS OFFICER | 955 0.0023% | $23.81 | $22,739 | -2.53% | |
2024-04-03 | Sale | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 152 0.0004% | $23.81 | $3,619 | -2.53% | |
2024-01-03 | Sale | Lee Kevin | Chief Executive Officer | 8,703 0.0207% | $17.50 | $152,303 | +30.55% | |
2024-01-03 | Sale | Skynner Michael | Chief Technology Officer | 2,643 0.0063% | $17.50 | $46,253 | +30.55% | |
2024-01-03 | Sale | Milnes Alistair | Chief Operating Officer | 2,643 0.0063% | $17.50 | $46,253 | +30.55% | |
2024-01-03 | Sale | Keen Nicholas | Chief Scientific Officer | 2,640 0.0063% | $17.50 | $46,200 | +30.55% | |
2024-01-03 | Sale | Crockett Nigel | Chief Business Officer | 2,643 0.0063% | $17.50 | $46,253 | +30.55% | |
2024-01-03 | Sale | Thompson Travis Alvin | Chief Accounting Officer | 604 0.0014% | $17.50 | $10,570 | +30.55% | |
2023-10-03 | Sale | Lee Kevin | Chief Executive Officer | 1,470 0.004% | $20.00 | $29,400 | +6.73% | |
2023-10-03 | Sale | Skynner Michael | Chief Technology Officer | 442 0.0012% | $20.00 | $8,840 | +6.73% | |
2023-10-03 | Sale | Keen Nicholas | Chief Scientific Officer | 272 0.0007% | $20.00 | $5,440 | +6.73% | |
2023-10-03 | Sale | Milnes Alistair | Chief Operating Officer | 442 0.0012% | $20.00 | $8,840 | +6.73% | |
2023-10-03 | Sale | Crockett Nigel | Chief Business Officer | 442 0.0012% | $20.00 | $8,840 | +6.73% | |
2023-10-03 | Sale | Thompson Travis Alvin | Chief Accounting Officer | 54 0.0001% | $20.00 | $1,080 | +6.73% | |
2023-07-03 | Sale | Lee Kevin | Chief Executive Officer | 1,498 0.005% | $25.10 | $37,600 | -12.19% |
Lee Kevin | Chief Executive Officer | 387270 0.9212% | $20.21 | 0 | 35 | |
Skynner Michael | Chief Technology Officer | 94884 0.2261% | $20.21 | 0 | 6 | |
Milnes Alistair | Chief Operating Officer | 72241 0.1727% | $20.21 | 0 | 6 | |
Keen Nicholas | Chief Scientific Officer | 62803 0.15% | $20.21 | 0 | 15 | |
Crockett Nigel | Chief Business Officer | 47761 0.1149% | $20.21 | 0 | 9 | |
Thompson Travis Alvin | Chief Accounting Officer | 23223 0.0551% | $20.21 | 0 | 4 | |
Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 22891 0.0539% | $20.21 | 0 | 1 | |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10 percent owner | 1957961 4.6195% | $20.21 | 1 | 0 | <0.0001% |
HARLAND DEBORAH | director | 1915275 4.5188% | $20.21 | 1 | 0 | <0.0001% |
GLAXOSMITHKLINE PLC | 10 percent owner | 1910531 4.5076% | $20.21 | 1 | 2 | <0.0001% |
SVLSF V, LLC | 10 percent owner | 1875637 4.4253% | $20.21 | 1 | 0 | <0.0001% |
Novartis Bioventures Ltd | 10 percent owner | 1769641 4.1752% | $20.21 | 1 | 0 | <0.0001% |
Anstey Michael | director | 1751437 4.1322% | $20.21 | 1 | 0 | <0.0001% |
Cambridge Innovation Capital (Jersey) Ltd | 10 percent owner | 1751437 4.1322% | $20.21 | 1 | 0 | <0.0001% |
NG CAROLYN | director | 571429 1.3482% | $20.21 | 1 | 0 | |
BINGHAM KATE | director | 38708 0.0913% | $20.21 | 1 | 2 | <0.0001% |
Smethurst Dominic | Chief Medical Officer | 36699 0.0866% | $20.21 | 0 | 1 | |
Kalowski Lee | President and CFO | 30309 0.0715% | $20.21 | 0 | 13 | |
Legault Pierre | director | 0 0% | $20.21 | 0 | 8 |
Baker Bros Advisors LP | $123.08M | 11.55 | 4.94M | +176.07% | +$78.5M | 1.55 | |
Deep Track Capital Lp | $86.91M | 8.16 | 3.49M | 0% | +$0 | 0.4 | |
Paradigm BioCapital Advisors LP | $80.84M | 7.59 | 3.25M | -12.41% | -$11.46M | 2.93 | |
Armistice Capital Llc | $41.63M | 3.91 | 1.67M | +8.85% | +$3.39M | 0.5 | |
Tybourne Capital Management HK Ltd | $38.47M | 3.61 | 1.55M | -6.38% | -$2.62M | 6.58 | |
Morgan Stanley | $37.77M | 3.55 | 1.52M | +47.37% | +$12.14M | <0.01 | |
First Light Asset Management | $29.71M | 2.79 | 1.19M | -23.05% | -$8.9M | 2.35 | |
Westfield Capital Management Co Lp | $25.87M | 2.43 | 1.04M | +13.26% | +$3.03M | 0.14 | |
Polar Capital | $25.01M | 2.35 | 1M | 0% | +$0 | 0.14 | |
Suvretta Capital Management, LLC | $22.77M | 2.14 | 914,476 | 0% | +$0 | 0.96 | |
Candriam S C A | $22.14M | 2.08 | 889,258 | +2.3% | +$498,000.00 | 0.14 | |
RA Capital Management, L.P. | $19.92M | 1.87 | 800,000 | 0% | +$0 | 0.02 | |
BlackRock | $14.32M | 1.34 | 575,030 | +14.63% | +$1.83M | <0.0001 | |
AXA | $13.8M | 1.3 | 554,163 | +0.01% | +$1,917.30 | 0.04 | |
Parkman Healthcare Partners Llc | $13.05M | 1.23 | 524,253 | +67.55% | +$5.26M | 1.61 | |
Camber Capital Management Lp | $11.21M | 1.05 | 450,000 | 0% | +$0 | 0.4 | |
Schonfeld Group | $10.48M | 0.98 | 420,800 | +293.27% | +$7.81M | 0.07 | |
T. Rowe Price | $10M | 0.94 | 401,646 | +45.08% | +$3.11M | <0.01 | |
Bank of America | $9.88M | 0.93 | 396,812 | -13.98% | -$1.61M | <0.01 | |
Point72 Asset Management | $8.53M | 0.8 | 342,594 | +51.66% | +$2.91M | 0.02 | |
Verition Fund Management Llc | $8.49M | 0.8 | 340,866 | -53.97% | -$9.95M | 0.09 | |
PLATINUM INVESTMENT MANAGEMENT LTD | $8.29M | 0.78 | 333,001 | -8.03% | -$724,067.11 | 0.11 | |
Kennedy Capital Management Inc | $6.28M | 0.59 | 252,172 | -39.45% | -$4.09M | 0.13 | |
Helm Capital Management LLC | $5.12M | 0.48 | 205,423 | 0% | +$0 | 0.15 | |
Duquesne Family Office Llc | $4.74M | 0.45 | 190,200 | New | +$4.74M | 0.13 | |
Handelsbanken | $4.48M | 0.42 | 179,800 | +28.61% | +$995,995.55 | 0.02 | |
Renaissance Technologies | $4.13M | 0.39 | 165,700 | +57.06% | +$1.5M | 0.01 | |
HighVista Strategies | $3.94M | 0.37 | 158,293 | 0% | +$0 | 1.45 | |
Soleus Capital Management, L.P. | $3.81M | 0.36 | 153,000 | +61.05% | +$1.44M | 0.04 | |
Voya Investment Management LLC | $3.41M | 0.32 | 136,775 | +20.88% | +$588,262.59 | <0.01 | |
Legal & General | $3.31M | 0.31 | 133,068 | +0.2% | +$6,538.18 | <0.01 | |
DAFNA Capital Management, LLC | $3.04M | 0.29 | 122,200 | 0% | +$0 | 0.71 | |
Trexquant Investment LP | $2.3M | 0.22 | 92,552 | -52.86% | -$2.58M | 0.03 | |
Ubs Oconnor Llc | $2.12M | 0.2 | 84,980 | +15.46% | +$283,337.10 | 0.18 | |
Pinnacle Associates, Ltd. | $1.99M | 0.19 | 80,090 | New | +$1.99M | 0.03 | |
Comerica | $1.96M | 0.18 | 78,770 | -3.76% | -$76,692.00 | 0.01 | |
Alphacentric Advisors Llc | $1.49M | 0.14 | 60,000 | New | +$1.49M | 0.95 | |
Citadel Advisors LLC | $1.48M | 0.14 | 59,440 | -79.81% | -$5.85M | <0.01 | |
Goldman Sachs | $1.38M | 0.13 | 55,450 | New | +$1.38M | <0.0001 | |
Td Asset Management Inc | $1.37M | 0.13 | 54,986 | +56.27% | +$493,019.86 | <0.01 | |
L&S Advisors, Inc. | $1.25M | 0.12 | 50,260 | +393.23% | +$997,743.00 | 0.16 | |
National Bank Of Canada Fi | $1.11M | 0.11 | 48,700 | New | +$1.11M | <0.01 | |
Two Sigma Advisers LP | $1.16M | 0.11 | 46,600 | -25.09% | -$388,614.30 | <0.01 | |
Harbor Capital Advisors Inc | $1.08M | 0.1 | 43,480 | +62.92% | +$418,255.20 | 0.14 | |
SEB | $1.06M | 0.1 | 42,729 | New | +$1.06M | 0.01 | |
Wexford Capital, LLC | $868,487.00 | 0.08 | 34,879 | 0% | +$0 | 0.19 | |
Allianz Asset Management Gmbh | $761,940.00 | 0.07 | 30,600 | 0% | +$0 | <0.01 | |
DekaBank | $700,000.00 | 0.07 | 30,000 | 0% | +$0 | <0.01 | |
Two Sigma | $711,766.00 | 0.07 | 28,585 | -72.42% | -$1.87M | <0.01 | |
The Manufacturers Life Insurance Company | $646,354.00 | 0.06 | 25,958 | +97.06% | +$318,346.40 | <0.01 |